OR WAIT null SECS
November 21, 2019
GE Healthcare Life Sciences has announced it will be working closely with Pharmadule Morimatsu to expand its KUBio “factory in a box” so that biopharma manufacturers will be able to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.
November 20, 2019
Through a partnership with the Sobti family, the CDMO will expand is injectable dosage form capabilities.
The new service will assist pharmaceutical companies with quality control and analytical requirements.
November 19, 2019
The companies will work to discover and develop therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology.
Alkermes plans to advance its investigational new drug-enabling capabilities for lead preclinical assets in the Rodin development candidate portfolio.
If successful, the acquisition will boost Recipharm’s global position in the contract development and manufacturing organization (CDMO) market.
November 18, 2019
Through the agreement, Roche will gain full rights to the company’s portfolio of molecules for fibrotic diseases, most notably PRM-151, Promedior’s lead product candidate.
November 14, 2019
With the gene-editing technology, Evotec will have the ability to accelerate research and enable the testing and development of new drugs.
The recent approval by FDA of Vumerity (diroximel fumarate), a new drug for treating multiple sclerosis, has a triggered a $150-million milestone payment from Biogen to Alkermes.
Bayer and Dewpoint Therapeutics have announced an option, research, and license agreement aimed at developing novel treatments for cardiovascular and gynecological diseases.